Foundations of Pharmacodynamic Systems Analysis

The pillars of pharmacodynamic modeling are the pharmacokinetics of the drug, the nature of the pharmacology that underlies drug interactions with their targets, and the physiology of the system considering molecular to whole body levels of organization and functioning. This chapter provides a general assessment of the fundamental components and some interactions of each of these pillars indicating how they serve as building blocks for systems models. Key elements of pharmacokinetics include the operation of Fick’s Laws for diffusion and perfusion along with the often nonlinear mechanisms of drug distribution and elimination. Target-binding relationships in pharmacology evolve from the law of mass action producing capacity-limitation in most operative control functions. Mammalian physiology and pathophysiology feature a wide breadth of turnover rates for biological compounds, structures, and functions ranging from rapid electrical signals to lengthy human lifespans, which often determine the rate-limiting process and basic type of model to be applied. Appreciation of the diverse array, mechanisms, and interactions of individual components that comprise the pillars of pharmacodynamics can serve as the foundation for building more complex systems models.

[1]  A. Atkinson,et al.  Analysis of the contributions of permeability and flow to intercompartmental clearance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[3]  W F Ebling,et al.  Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? , 1996, Journal of pharmaceutical sciences.

[4]  W. Jusko,et al.  Pharmacokinetics of Capacity‐Limited Systems , 1989, Journal of clinical pharmacology.

[5]  G. Adair THE HEMOGLOBIN SYSTEM VI. THE OXYGEN DISSOCIATION CURVE OF HEMOGLOBIN , 1925 .

[6]  W J Jusko,et al.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.

[7]  Wojciech Krzyzanski,et al.  Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  Benjamin Gompertz,et al.  XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c , 1825, Philosophical Transactions of the Royal Society of London.

[9]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[10]  Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[12]  William J. Jusko,et al.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  J. V. van Rossum,et al.  Affinity, intrinsic activity and drug interactions. , 1957, Pharmacological reviews.

[14]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[15]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. J. Clark The Rate of Action of Drugs on Cells , 1937 .

[17]  E. Starling On the Absorption of Fluids from the Connective Tissue Spaces , 1896, The Journal of physiology.

[18]  Richard R. Almon,et al.  Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[19]  R. Ramakrishnan,et al.  Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[21]  A. Fick V. On liquid diffusion , 1855 .

[22]  D. Swinney The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.

[23]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[24]  Donald E Mager,et al.  Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. , 2012, Cancer research.

[25]  T Iga,et al.  Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. , 1996, Biological & pharmaceutical bulletin.

[26]  W. Jusko,et al.  Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats , 2012, Pharmaceutical Research.

[27]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  W. Jusko,et al.  Inhibition of Rat Splenocyte Proliferation with Methylprednisolone: In Vivo Effect of Liposomal Formulation , 1994, Pharmaceutical Research.

[29]  J. Shannon RENAL TUBULAR EXCRETION , 1939 .

[30]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[31]  T. Brailsford Robertson,et al.  The chemical basis of growth and senscence , 1923 .

[32]  Jianguo Zhi,et al.  Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[33]  G Levy,et al.  Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.

[34]  Alan Forrest,et al.  Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.

[35]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[36]  S. Loewe,et al.  Über Kombinationswirkungen , 1926, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[37]  Richard R Almon,et al.  Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.

[38]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[39]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[40]  W. Jusko,et al.  Assessment of Basic Indirect Pharmacodynamic Response Models with Physiological Limits , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[41]  Wojciech Krzyzanski,et al.  Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[42]  D. Colquhoun Pharmacologic Analysis of Drug–Receptor Interaction (3rd edn) , 1998 .

[43]  D R Mould,et al.  Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.

[44]  W. Jusko,et al.  ALGORITHM FOR APPLICATION OF FOURIER ANALYSIS FOR BIORHYTHMIC BASELINES OF PHARMACODYNAMIC INDIRECT RESPONSE MODELS , 2000, Chronobiology international.

[45]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[46]  W. Jusko,et al.  Pharmacoimmunodynamic interactions of interleukin‐10 and prednisone in healthy volunteers , 1999, Clinical pharmacology and therapeutics.

[47]  M. Danhof,et al.  In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.

[48]  Yasuhiko Yamada,et al.  Parmacodynamic Analysis of Antiplatelet Effect of Aspirin in the Literature. Modeling Based on Inhibition of Cyclooxygenase in the Platelet and the Vessel Wall Endothelium. , 1996 .

[49]  A. Goldstein The interactions of drugs and plasma proteins. , 1949, The Journal of pharmacology and experimental therapeutics.

[50]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[51]  Renkin Em Relation of capillary morphology to transport of fluid and large molecules: a review. , 1979 .

[52]  Malcolm Rowland,et al.  Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[53]  D. DuBois,et al.  Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPS-Induced Inflammation in Rats , 2012, Pharmaceutical Research.

[54]  Siddharth Sukumaran,et al.  Meta-Modeling of Methylprednisolone Effects on Glucose Regulation in Rats , 2013, PloS one.

[55]  W. Jusko,et al.  Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. , 2004, Journal of veterinary pharmacology and therapeutics.

[56]  William J Jusko,et al.  Moving from basic toward systems pharmacodynamic models. , 2013, Journal of pharmaceutical sciences.